Xiao-Jia Wang (Xiaojia Wang, Xiaojiao Wang)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 29

Top Venues

Nature medicine

Breast cancer (Tokyo, Japan)

Nature communications

Medicine

Zhejiang Cancer Hospital

Zhejiang University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zhejiang Cancer Hospital Mar 03 2003

China

Directoe :: Breast mendical oncology

Education History

Zhejiang University Sep 01 1997 - Jun 29 2002

China

PHD

Publications

Huan-Ping Zhang, Rui-Yuan Jiang, Jia-Yu Zhu, Ke-Na Sun, Yuan Huang, Huan-Huan Zhou, Ya-Bing Zheng, Xiao-Jia Wang
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Huan-Ping Zhang, Rui-Yuan Jiang, Jia-Yu Zhu, Ke-Na Sun, Yuan Huang, Huan-Huan Zhou, Ya-Bing Zheng, Xiao-Jia Wang
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine (2024)
Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Hai-Bo Wang, Yongmei Yin, Xiao-Jia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shu-Sen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yi-Ding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yue-Yin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nature medicine 30 (1) (2024)
Huan-Ping Zhang, Rui-Yuan Jiang, Jia-Yu Zhu, Ke-Na Sun, Yuan Huang, Huan-Huan Zhou, Ya-Bing Zheng, Xiao-Jia Wang
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Huan-Ping Zhang, Rui-Yuan Jiang, Jia-Yu Zhu, Ke-Na Sun, Yuan Huang, Huan-Huan Zhou, Ya-Bing Zheng, Xiao-Jia Wang
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast cancer (Tokyo, Japan) (2024)
Huan-Ping Zhang, Rui-Yuan Jiang, Jia-Yu Zhu, Ke-Na Sun, Yuan Huang, Huan-Huan Zhou, Ya-Bing Zheng, Xiao-Jia Wang
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Wei Wang, Jiayi Wu, Keyu Chen, Xiao-Jia Wang, Xiying Shao
Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review. Technology in cancer research & treatment 22 (2023)
Wei Wang, Jiayi Wu, Keyu Chen, Xiao-Jia Wang, Xiying Shao
Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review. Technology in cancer research & treatment 22 (2023)
Yabing Zheng, Wen-Ming Cao, Xiying Shao, Yanxia Shi, Li Cai, Wenyan Chen, Jian Liu, Peng Shen, Yi-Ding Chen, Xian Wang, Huiping Li, Man Li, Zhanhong Chen, Xiao-Jia Wang
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. Nature communications 14 (1) (2023)
Rui-Yuan Jiang, Zi-Ru Fang, Huan-Ping Zhang, Jun-Yao Xu, Jia-Yu Zhu, Ke-Yu Chen, Wei Wang, Xiao Jiang, Xiao-Jia Wang
Ginsenosides: changing the basic hallmarks of cancer cells to achieve the purpose of treating breast cancer. Chinese medicine 18 (1) (2023)
Jiayi Wu, Wei Wang, Xiying Shao, Guang Lin, Xiao-Jia Wang
Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review. Medicine 101 (51) (2023)
Yabing Zheng, Wen-Ming Cao, Xiying Shao, Yanxia Shi, Li Cai, Wenyan Chen, Jian Liu, Peng Shen, Yi-Ding Chen, Xian Wang, Huiping Li, Man Li, Zhanhong Chen, Xiao-Jia Wang
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. Nature communications 14 (1) (2023)
Yabing Zheng, Wen-Ming Cao, Xiying Shao, Yanxia Shi, Li Cai, Wenyan Chen, Jian Liu, Peng Shen, Yi-Ding Chen, Xian Wang, Huiping Li, Man Li, Zhanhong Chen, Xiao-Jia Wang
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. Nature communications 14 (1) (2023)
Zi-Yan Yang, Jianguo Feng, Ji Jing, Yuan Huang, Wei-Wu Ye, Lei Lei, Xiao-Jia Wang, Wen-Ming Cao
Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. NPJ breast cancer 9 (1) (2023)
Jiayi Wu, Wei Wang, Xiying Shao, Guang Lin, Xiao-Jia Wang
Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review. Medicine 101 (51) (2023)
Zi-Yan Yang, Jianguo Feng, Ji Jing, Yuan Huang, Wei-Wu Ye, Lei Lei, Xiao-Jia Wang, Wen-Ming Cao
Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. NPJ breast cancer 9 (1) (2023)
Wei Wang, Jiayi Wu, Keyu Chen, Xiao-Jia Wang, Xiying Shao
Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review. Technology in cancer research & treatment 22 (2023)
Jiayi Wu, Wei Wang, Xiying Shao, Guang Lin, Xiao-Jia Wang
Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review. Medicine 101 (51) (2023)
Yabing Zheng, Wen-Ming Cao, Xiying Shao, Yanxia Shi, Li Cai, Wenyan Chen, Jian Liu, Peng Shen, Yi-Ding Chen, Xian Wang, Huiping Li, Man Li, Zhanhong Chen, Xiao-Jia Wang
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. Nature communications 14 (1) (2023)
Jie Sun, Futao Chu, Jia-Ni Pan, Yaxin Zhang, Lu Yao, Jiuan Chen, Li Hu, Juan Zhang, Ye Xu, Xiao-Jia Wang, Wen-Ming Cao, Yuntao Xie
BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Jia-Ni Pan, Lei Lei, Wei-Wu Ye, Xiao-Jia Wang, Wen-Ming Cao
BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis. Journal of breast cancer 24 (5) (2021)
Jiahuan Huang, Lei Lei, Bo Chen, Guoqiang Pan, Xiao-Jia Wang, Meiyu Fang
Remarkable Response of Toripalimab Combined with Chemotherapy in Sarcomatoid Carcinoma of Palatine Tonsil: A Case Report. Journal of multidisciplinary healthcare 14 (2021)
Zi-Yan Yang, Liu Yang, Chun-Wei Xu, Xiao-Jia Wang, Lei Lei
An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway. Biology open 9 (1) (2020)
Zhanhong Chen, Tian Sun, Zi-Yan Yang, Yabing Zheng, Ruoying Yu, Xue Wu, Junrong Yan, Yang W Shao, Xiying Shao, Wen-Ming Cao, Xiao-Jia Wang
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Molecular genetics & genomic medicine 8 (2) (2019)

Xiao-Jia Wang.css-eqlu8i{font-size:small;padding-left:4px;} (Xiaojia Wang, Xiaojiao Wang)

Publication Activity (10 Years)

Top Topics

Top Venues

Xiao-Jia Wang (Xiaojia Wang, Xiaojiao Wang)